International Journal of STD & AIDS > Volume 18, Number 12 > Pp. 832-834

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sungkanuparph, S. Articles by Sathapatayavongs, B. Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Original research articles

HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen

Somnuek Sungkanuparph, Sasisopin Kiertiburanakul, Anucha Apisarnthanarak, Kumthorn Malathum and Boonmee Sathapatayavongs

Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Faculty of Medicine, Thammasart University Hospital, Pratumthani, Thailand, Thailand; Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have a longer half-life than nucleoside reverse transcriptase inhibitor (NRTIs). Simultaneous interruption of all drugs exposes the patients to NNRTI monotherapy. This study evaluated HIV-1 genotype after treatment interruption (TI) of NNRTI-based antiretroviral therapy (ART) and virological response after resumption of the same ART regimen. A prospective study was conducted in HIV-1-infected patients who enrolled into a CD4-guided TI study. All patients continued dual NRTIs for a further 7–10 days at NNRTI TI. HIV-1 genotypic assay was performed prior to resumption of the same ART regimen. Forty-three patients required ART resumption after TI from NNRTI-based regimens. Mean age was 42.7 years; 44% were men. Median CD4 and HIV-1 RNA at the time of ART resumption were 178 cell/mm³ and 5.78 log copies/mL, respectively. HIV-1 genotype revealed no mutations contributed to NRTI or NNRTI resistance. Of all, 56% and 100% patients achieved undetectable HIV-1 RNA at three and six months, respectively. Median CD4 were 386 and 419 cells/mm³ at the corresponding periods. In conclusion, continuation of dual NRTIs for 7–10 days after TI of NNRTI-based regimens can minimize the risk of acquired NNRTI resistance. With this strategy, the same regimen can be used for resumption and also yield good virological and immunological outcomes.

Key Words: HIV • GENOTYPE • TREATMENT INTERRUPTION • NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) • ANTIRETROVIRAL THERAPY • TREATMENT OUTCOME

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?